Dosing of intraarticular triamcinolone hexacetonid for knee synovitis in chronic polyarthritis

INTERVENTION: Trade Name: triamcinolone hexacetonide (Lederspan) Product Name: triamcinolone hexacetonid (Lederspan) Product Code: 9512 Pharmaceutical Form: Injection Trade Name: triamcinolone hexacetonide (Lederspan) Product Name: triamcinolone hexacetonid (Lederspan) Product Code: 9512 Pharmaceutical Form: Injection CONDITION: Psoriatic arthritis and rheumatoid arthritis with synovitis of the knee Therapeutic area: Diseases [C] ‐ Musculoskeletal Diseases [C05] PRIMARY OUTCOME: Main Objective: To study the relapse rate after intraaarticular triamcinolone hexacetonide (20 vs 40 mg) treatment for knee synovitis in patients with rheumatoid arthritis and psoriatic arthritis Primary end point(s): Recurrence of knee symptoms and confirmed synovitis on a clinical examination Secondary Objective: Not applicable Timepoint(s) of evaluation of this end point: At relapse , during visits according to clinical routines and a phone call after 6 months SECONDARY OUTCOME: Secondary end point(s): Not applicable Timepoint(s) of evaluation of this end point: Not applicable INCLUSION CRITERIA: Age > 18 years chronic polyarthritis (psoriatic arthritis or rheumatoid arthritis) Synovitis of the knee acceptance to participate in the study Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18‐64 years) yes F.1.2.1 Number of subjects for this age range 100 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 60